Reactogenicity, Safety and Immunogenicity of a TB/FLU-01L Tuberculosis Vaccine

A Randomized, Open Clinical Trial Phase 1 Vaccine TB/FLU-01L by Intranasal and Sublingual Application for Specific Immunotherapy Pulmonary Tuberculosis

The study is a single centre, phase I, open, randomized, by intranasal and sublingual application trial that explored the safety and immunogenicity of 2 doses (Day 1 and Day 21) TB/FLU-01L tuberculosis vaccine in BCG-vaccinated healthy adult subjects aged 18-50 years.

Study Overview

• Status: Completed
• Conditions: Tuberculosis
• Intervention / Treatment: Biological: TB/FLU-01L; Biological: TB/FLU-01L

• Study Type: Interventional
• Enrollment (Actual): 36
• Phase: Phase 1

Contacts and Locations

Study Locations

• Kazakhstan
  • Almaty
    • Almaty Qalasy, Almaty, Kazakhstan, 050000
      • National Center for Tuberculosis Problems, Kazakhstan

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 50 years (Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Healthy BCG-vaccinated male or female adult 18 through 50 years of age at the enrollment visit.
• Literate and willing to provide written informed consent.
• A signed informed consent.
• Capable and willing to complete diary cards and willing to return for all follow-up visits.
• For females, willing to take reliable birth control measures throughout the entire period of participation in the study

Exclusion Criteria:

• Clinical, radiological (chest X-ray) or laboratory evidence of active or past TB disease.
• Current or past administration of anti-TB therapy.
• History of contact with TB patients.
• Positive QuantiFERON-TB Gold test.
• BCG vaccination in less than 6 months prior to study.
• Practice of nasal irrigation on a regular basis within the past six months or has engaged in nasal irrigation within two weeks prior to enrollment.
• Recent history of frequent nose bleeds (>5 within the past year).
• Clinically relevant abnormal paranasal anatomy.
• Recent history (within the past month) of rhino or sinus surgery, or surgery for any traumatic injury of the nose.
• Current or recent (within two weeks of enrollment) acute respiratory illness with or without fever.
• Hypersensitivity after previous administration of any vaccine.
• History of chronic alcohol abuse and/or illegal drug use.
• Any clinically significant abnormal laboratory finding.
• A positive pregnancy test for all women of childbearing potential.
• Administration of immunosuppressive drugs or other immune modifying drugs within 4 weeks prior to study enrollment.
• Acute or chronic clinically significant pulmonary disease, cardiovascular disease, gastrointestinal disease, liver disease, neurological illness, liver disease, blood disease, skin disorder, endocrine disorder, neurological illness and psychiatric disorder as determined by medical history, physical examination or clinical laboratory screening tests, which in the opinion of the investigator, might interfere with the study objectives.
• History of leukemia or any other blood or solid organ cancer.
• Seropositive for HIV, hepatitis B surface antigen and/or hepatitis C antibodies.
• Receipt of antivirals, antibiotics, immunoglobulins or other blood products within 4 weeks prior to study enrollment or planned receipt of such products during the period of subject participation in the study.
• Participation in another clinical trial within the previous three months or planned enrollment in such a trial during the period of this study.
• Subjects who are, in the opinion of the investigator, at significantly increased risk of non-cooperation with requirements of the study protocol.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: TB/FLU-01L (intranasal application); Vaccine safety analysis of TB/FLU-01L at double intranasal application in healthy volunteers aged 18 to 50 years.	Biological: TB/FLU-01L; TB / FLU-01L (intranasal application); Biological: TB/FLU-01L; TB/FLU-01L (sublingual application)
Active Comparator: TB/FLU-01L (sublingual application); Vaccine safety analysis of TB/FLU-01L at double sublingual application in healthy volunteers aged 18 to 50 years.	Biological: TB/FLU-01L; TB / FLU-01L (intranasal application); Biological: TB/FLU-01L; TB/FLU-01L (sublingual application)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Adverse Events (AE) - Immediate reactions	Commonly Solicited Local reactions associated with injections: pain, erythema/redness, swelling, induration, bruising at the injection site.	Two hours
Solicited local and systemic reactions	Commonly Solicited general symptoms: fever (oral temperature ≥ 38.0°C), chills, muscle aches/myalgia, arthralgia, fatigue, malaise, headache, rash, sweating, nausea, vomiting, diarrhea and potential indicators of oculo-respiratory syndrome* (ORS).	Greater than 2 hours after administration of any dose of vaccine through 7 days following any dose
Unsolicited AEs	Unsolicited AEs are any untoward medical occurrence in the subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product	Greater than 2 hours after administration of any dose of vaccine or placebo through 7 days following any dose
Serious adverse events (SAEs), including abnormal laboratory findings	Serious adverse events (SAEs) are medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.	Three weeks of receipt of any dose

Collaborators and Investigators

• Sponsor: Research Institute for Biological Safety Problems
• Collaborators: Research Institute of Influenza, Russia; Ministry of Health, Kazakhstan
• Investigators: Principal Investigator: Berik M Khairullin, PhD, Research Institute for Biological Safety Problems

Study record dates

Study Major Dates

• Study Start: October 1, 2013
• Primary Completion (Actual): April 1, 2014
• Study Completion (Actual): February 1, 2015

Study Registration Dates

• First Submitted: January 4, 2017
• First Submitted That Met QC Criteria: January 10, 2017
• First Posted (Estimate): January 11, 2017

Study Record Updates

• Last Update Posted (Estimate): January 11, 2017
• Last Update Submitted That Met QC Criteria: January 10, 2017
• Last Verified: January 1, 2017

More Information

Terms related to this study

• Keywords: vaccine; tuberculosis; influenza vector
• Additional Relevant MeSH Terms: Infections; Bacterial Infections; Bacterial Infections and Mycoses; Gram-Positive Bacterial Infections; Actinomycetales Infections; Mycobacterium Infections; Tuberculosis
• Other Study ID Numbers: VIT-I-01/2013

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED